If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Humulin® Therapies
Humulin® R (U-100) (regular insulin human injection, USP [rDNA origin])
100 units/mLHumulin® R (U-500) (regular U-500 [concentrated] insulin human injection, USP [rDNA origin])
500 units/mLHumulin® 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin])
100 units/mLHumulin® N U-100 (human insulin [rDNA origin] isophane suspension)
100 units/mLThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Humulin® R U-500 (insulin human) be administered intravenously?
Do not administer Humulin R U-500 intravenously. Humulin R U-500 should be injected subcutaneously into the thigh, upper arm, abdomen, or buttocks.
Route of Administration
Do not administer Humulin® R U-500 (insulin human injection) 500 units/mL (U-500R) intravenously.1
The efficacy and safety of U-500R delivered by continuous subcutaneous insulin infusion has not been determined.1
To reduce the risk of hypoglycemia,
- do not administer U-500R intravenously, or via an insulin pump, and
- do not dilute or mix U-500R with any other insulin products or solutions.1
Patients should inject their prescribed dose of U-500R subcutaneously into the
- thigh
- upper arm
- abdomen, or
- buttocks.1
Injection sites should be rotated within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis.1
Enclosed Prescribing Information
Reference
1Humulin R U-500 [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: December 24, 2024